骨癌治疗市场规模- 按类型（原发性、[骨肉瘤、软骨肉瘤]、继发性）、治疗（标靶和免疫治疗[狄诺塞麦、伊马替尼]、化疗[阿霉素、顺铂]）、治疗提供者和预测，2024 - 2032 年

Bone Cancer Treatment Market Size - By Type (Primary, [Osteosarcoma, Chondrosarcoma], Secondary), Treatment (Targeted and Immunotherapy [Denosumab, Imatinib], Chemotherapy [Doxorubicin, Cisplatin]), Treatment Provider & Forecast, 2024 - 2032

出版日期: 2024年05月22日 | 出版商:

Global Market Insights Inc. | 英文 226 Pages | 商品交期: 2-3个工作天内

价格

简介目录

全球骨癌治疗市场在 2024 年至 2032 年间将经历 5% 的复合年增长率，更好的诊断技术将透过实现准确检测彻底改变骨癌管理。根据美国癌症协会 (ACS) 的报告，过去十年先进影像技术的使用增加了约 15%，有助于早期诊断的增加和治疗结果的改善。

诊断创新促进了精确的肿瘤定位和基因分析，有助于根据个别患者的需求量身定制治疗计划。早期发现可以提高治疗效果并提高存活率。此外，患者对个人化治疗的偏好的转变以及医疗保健提供者的积极主动的方法将增强未来几年的行业动态。

整个骨癌治疗市场根据类型、治疗、治疗提供者和地区进行分类。

由于原发性癌症转移的普遍存在，到 2032 年，次要部分将出现显着的复合年增长率。由于初始治疗的创新，原发性癌症（例如乳腺癌或前列腺癌）患者的寿命更长，继发性骨癌是一个重大问题。这种转变导致对骨转移的专门治疗的需求更高。医学影像和监测的改进加强了继发性骨癌的检测，从而实现早期干预。这些因素导致对继发性骨癌治疗的需求不断增长。

由于新型化疗药物的疗效和可用性不断提高，到 2032 年，化疗领域将占据显着的骨癌治疗市场。这些药物在治疗局部骨癌和转移性骨癌方面显示出改善的结果，为患者提供了更有效的治疗选择。众所周知，化疗可以缩小肿瘤大小并控制疾病进展。此外，联合疗法和个人化化疗方案的进步正在提高治疗效果，促进细分市场的成长。

由于人口老化和骨癌盛行率增加，2024年至2032年欧洲骨癌治疗市场将录得令人印象深刻的复合年增长率。该地区拥有增强的医疗基础设施和先进的治疗选择。对尖端研究的大量投资以及对提供全面护理的关注正在改善患者的治疗效果。此外，意识的提高和早期检测计划正在导致更高的诊断率，从而推动了对有效治疗解决方案的需求。随着医疗保健系统的发展和资源的扩大，欧洲对先进骨癌治疗的需求将继续呈上升趋势。

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

Advaxis Inc.
Amgen Inc.
Atlanthera
Baxter International Inc.
Bayer AG
Debiopharm
Eli Lilly and Company
Gradalis Inc.
Hikma Pharmaceutical PLC
Johnson & Johnson
Novartis AG
Pfizer Inc.
Recordati Group
Spectrum Pharmaceuticals Inc.
Takeda Pharmaceutical Company

简介目录

Product Code: 9585

Global Bone Cancer Treatment Market will experience a 5% CAGR between 2024 and 2032, ascended by better diagnostic techniques that revolutionize bone cancer management by enabling accurate detection. According to the American Cancer Society (ACS) reports, the use of advanced imaging techniques has increased by about 15% over the past decade, contributing to a rise in early-stage diagnoses and improved management outcomes.

The diagnostic innovations facilitate precise tumor localization and genetic profiling, which help in tailoring treatment plans to individual patient needs. Early detection boosts treatment outcomes as well as enhances survival rates. Further, the shifting preference for personalized treatment among patients and proactive approach by healthcare providers will augment the industry dynamics in the coming years.

The overall bone cancer treatment market is classified based on type, treatment, treatment provider, and region.

The secondary segment will register a remarkable CAGR through 2032, due to the prevalence of metastasis from primary cancers. As patients with primary cancers, such as breast or prostate cancer, live longer due to innovations in initial treatments, secondary bone cancer is a significant concern. This shift results in a higher need for specialized treatments targeting bone metastases. Improvements in medical imaging and monitoring have strengthened the detection of secondary bone cancers, leading to earlier intervention. These factors contribute to the thriving demand for secondary bone cancer treatments.

The chemotherapy segment will clutch a notable bone cancer treatment market share by 2032, because of the increasing efficacy and availability of novel chemotherapy agents. These agents are showing improved outcomes in managing both localized and metastatic bone cancer, providing patients with more effective treatment options. Chemotherapy is known to reduce tumor size and control disease progression. Additionally, advancements in combination therapies and personalized chemotherapy regimens are enhancing treatment efficacy, escalating segment growth.

Europe bone cancer treatment market will record an impressive CAGR from 2024 to 2032, owing to an aging population and increased prevalence of bone cancer. The region boasts enhanced healthcare infrastructure and advancements in treatment options. The inflowing investment in cutting-edge research and focus on offering comprehensive care are resulting in improved patient outcomes. Additionally, increased awareness and early detection programs are leading to higher diagnosis rates, fueling the need for effective treatment solutions. As healthcare systems evolve and resources expand, the demand for advanced bone cancer treatments will continue its upward trajectory in Europe.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of bone cancer
  - 3.2.1.2 Growing awareness and early diagnosis
  - 3.2.1.3 Advancements in medical technology and treatment modalities
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High treatment costs
  - 3.2.2.2 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Primary bone cancer
- 5.2.1 Osteosarcoma
- 5.2.2 Chondrosarcoma
- 5.2.3 Ewing sarcoma
- 5.2.4 Other primary bone cancer
5.3 Secondary bone cancer

Chapter 6 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Targeted and immunotherapy
- 6.2.1 Denosumab
- 6.2.2 Imatinib
- 6.2.3 Sunitinib
- 6.2.4 Other targeted & immunotherapies
6.3 Chemotherapy
- 6.3.1 Doxorubicin
- 6.3.2 Cisplatin
- 6.3.3 Etoposide
- 6.3.4 Cyclophosphamide
- 6.3.5 Other chemotherapies
6.4 Radiation therapy
6.5 Surgery

Chapter 7 Market Estimates and Forecast, By Treatment Provider, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Oncology centers & specialty clinics
7.4 Ambulatory surgical centers (ASCs)

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa